Loading...
Loading...
UNCY| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 7.4M |
| Operating I/L | -7.4M |
| Other Income/Expense | 17.3M |
| Interest Income | 0.5M |
| Pretax | 9.9M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | 3.9M |
Unicycive Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for kidney diseases. The company's primary revenue stream comes from the development and commercialization of Renazorb, a treatment for hyperphosphatemia in chronic kidney disease patients, and UNI 494, designed for acute kidney injury treatment.
